Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PGEN – Precigen, Inc.

Float Short %

19.53

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

0.06

EPS Last/This Y

0.05

EPS This/Next Y

0.49

Price

4.18

Target Price

8.25

Analyst Recom

1.5

Performance Q

200.72

Relative Volume

3.97

Beta

1.66

Ticker: PGEN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PGEN1.580.304.8152271
2025-07-28PGEN1.5850.340.0155544
2025-07-29PGEN1.580.332.5756712
2025-07-30PGEN1.730.4010.9660794
2025-07-31PGEN1.7050.330.1457714
2025-08-01PGEN1.6750.320.0258633
2025-08-04PGEN1.7550.320.0559810
2025-08-05PGEN1.930.310.0560285
2025-08-06PGEN1.830.260.5172228
2025-08-07PGEN1.890.330.06103855
2025-08-08PGEN1.7850.294.25116341
2025-08-11PGEN1.740.310.04118624
2025-08-12PGEN1.80.280.07129818
2025-08-13PGEN1.910.250.27147895
2025-08-14PGEN1.850.255.11162365
2025-08-15PGEN2.910.300.20169141
2025-08-18PGEN2.950.330.80166827
2025-08-19PGEN3.180.350.44174623
2025-08-20PGEN3.210.350.44185210
2025-08-21PGEN3.640.350.16186696
2025-08-22PGEN4.180.380.13177900
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PGEN1.5719.9- -0.37
2025-07-28PGEN1.5819.9- -0.37
2025-07-29PGEN1.5719.9- -0.37
2025-07-30PGEN1.7319.9- -0.37
2025-07-31PGEN1.7119.9- -0.37
2025-08-01PGEN1.6719.9- -0.37
2025-08-04PGEN1.7619.9- -0.37
2025-08-05PGEN1.9319.9- -0.37
2025-08-06PGEN1.8419.9- -0.37
2025-08-07PGEN1.8819.9- -0.37
2025-08-08PGEN1.7819.9- -0.37
2025-08-11PGEN1.7419.9- -0.37
2025-08-12PGEN1.8019.9- -0.37
2025-08-13PGEN1.9119.9- -0.37
2025-08-14PGEN1.8519.9- -0.37
2025-08-15PGEN2.9319.9- -0.40
2025-08-18PGEN2.950.0- -0.40
2025-08-19PGEN3.2219.9- -0.40
2025-08-20PGEN3.2119.9- -0.40
2025-08-21PGEN3.640.0- -0.40
2025-08-22PGEN4.180.0- -0.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PGEN0.007.1419.44
2025-07-28PGEN0.007.3519.44
2025-07-29PGEN0.007.3519.44
2025-07-30PGEN0.007.3519.44
2025-07-31PGEN0.007.3519.44
2025-08-01PGEN0.007.3519.44
2025-08-04PGEN0.007.3019.44
2025-08-05PGEN0.007.3019.44
2025-08-06PGEN0.007.3019.44
2025-08-07PGEN0.007.3019.44
2025-08-08PGEN0.007.3019.44
2025-08-11PGEN0.007.3319.44
2025-08-12PGEN0.007.3319.71
2025-08-13PGEN0.007.3319.71
2025-08-14PGEN0.007.3319.71
2025-08-15PGEN0.007.3319.53
2025-08-18PGEN0.006.6519.53
2025-08-19PGEN0.006.6519.53
2025-08-20PGEN0.006.6519.53
2025-08-21PGEN0.006.6519.53
2025-08-22PGEN0.006.6519.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

Institutional Transactions

6.65

Beta

1.66

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

14

Fair Value

Quality Score

44

Growth Score

33

Sentiment Score

90

Actual DrawDown %

62.3

Max Drawdown 5-Year %

-93.8

Target Price

8.25

P/E

Forward P/E

PEG

P/S

286.99

P/B

P/Free Cash Flow

EPS

-0.43

Average EPS Est. Cur. Y​

-0.42

EPS Next Y. (Est.)

0.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2868.66

Relative Volume

3.97

Return on Equity vs Sector %

313.8

Return on Equity vs Industry %

326.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

Precigen, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 143
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
stock quote shares PGEN – Precigen, Inc. Stock Price stock today
news today PGEN – Precigen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PGEN – Precigen, Inc. yahoo finance google finance
stock history PGEN – Precigen, Inc. invest stock market
stock prices PGEN premarket after hours
ticker PGEN fair value insiders trading